News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
The wholly owned subsidiary will carry on the business of all types of research and development and other related services
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Subscribe To Our Newsletter & Stay Updated
